THE Compounding Pharmacy Pathway 503a 503b

The three peptide pathways

When you decide to take a peptide, you’re choosing one of three pathways, each with different regulatory positioning, supply chain, cost, and access mechanics.

Pathway 1 — FDA-approved prescription drug

You go to a doctor, they write a prescription for an FDA-approved peptide for its FDA-approved indication, you fill it at a regular pharmacy or specialty pharmacy. The molecule has been through full clinical trials, has FDA-approved labeling, has known dosing + safety profile + monitoring requirements. This is the path for semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta) for HIV-associated lipodystrophy, PT-141 / Bremelanotide (Vyleesi) for HSDD in women, oxytocin (Pitocin/Syntocinon), and the (very) small handful of other peptides that have made it through the full FDA approval process. Highest cost, highest regulatory grade, narrowest indication scope (you can only get them for the FDA-approved indication unless your doctor writes them off-label, which is its own conversation).

Pathway 2 — Compounding pharmacy (503A or 503B)

A pharmacy with the right licensing and infrastructure prepares the peptide either patient-specifically (503A) or in larger batches (503B). The compound has to meet specific FDA eligibility criteria. Cost is meaningfully lower than brand-name FDA-approved, but still substantially higher than research-chemical pricing. Quality is pharmaceutical-grade (CGMP — Current Good Manufacturing Practice). The catch: most popular peptides cannot legally be compounded right now. This article explains why.

Pathway 3 — Research chemical

You buy from a research-chemical vendor (Alyve, AminoClub, BioLongevity, others) labeled “for research use only, not for human consumption.” Cost is dramatically lower (often 5–10× cheaper than compounded pharma-grade). Regulatory positioning is genuinely gray. Quality varies enormously across the vendor universe — see How to read a peptide Certificate of Analysis (and spot a fake) for the verification framework. The molecule itself, in most cases, was synthesized in China — see Where peptides are actually made — the global manufacturing reality for that context. The OHM-recommended path within this lane is verified-vendor + third-party COA discipline. The supply-chain reality is the same one Pathway 2 compounding pharmacies have to navigate at the API level, but at a different price point and with different accountability.

Each pathway has different mechanics, different costs, different regulatory exposure, and different available compounds. The right pathway depends on which compound you want, what indication, your budget, your supervision needs, and your tolerance for regulatory gray zones.

503A vs 503B compounding pharmacies — the structural distinction

Within Pathway 2, there are two different kinds of compounding pharmacies, governed by two different sections of FDA law.

503A — traditional compounding pharmacy. Does patient-specific compounding pursuant to a specific prescription for a specific patient. Smaller scale operationally. Can compound any drug that meets the FDA’s eligibility criteria for compounding (more on those criteria below). The vast majority of independent compounding pharmacies in your local area operate as 503As.

503B — outsourcing facility. Can manufacture larger-scale finished products WITHOUT a specific patient prescription. More restrictive: limited to substances on the 503B Category 1 bulks list OR substances on the FDA shortage list. Higher regulatory burden (full CGMP requirements equivalent to pharmaceutical manufacturers). Approximately 92 registered 503Bs currently exist in the US. Most pharmacies are NOT 503Bs; the registration burden + CGMP infrastructure cost is substantial.

The FDA also clarified in 2023 that a 503B can manufacture finished product and sell it to a 503A pharmacy for patient-specific dispensing pursuant to a prescription. The 503B cannot wholesale (no selling to doctor’s offices or distributing broadly), but the 503A pharmacy can dispense a 503B-made product to its patients. This created a third common operational model where 503As partner with 503Bs to access compounds the 503A can’t make in-house.

The Bulk Substances List — the regulatory framework that decides what's compoundable

Here’s the central mechanism. The FDA maintains a regulatory list called the Bulk Substances List that categorizes peptides and other compounds into one of three buckets for compounding eligibility:

Category 1 — Eligible for compounding

APIs (active pharmaceutical ingredients) approved for use in compounding even without a USP monograph or FDA-approved human drug status. Eligible for 503A compounding. This is the green-light category.

Category 2 — “Do not compound”

Substances FDA continues to evaluate for safety. Significant safety concerns that prevent compounding eligibility while review is ongoing. NOT eligible for compounding. This is the red-light category.

“Jury Still Out” — removed from Category 2 but not yet on Category 1

The September 2024 regulatory limbo. Substances REMOVED from the “do not compound” list but NOT YET officially placed on the “approved for compounding” list. Technically not banned, technically not approved. FDA uses “enforcement discretion” here because they bear the burden of proving non-compliance. Multiple high-interest peptides currently sit in this limbo.

The fourth eligibility path: “component of an FDA-approved human drug”

A 503A pharmacy can compound an API that is a component of an FDA-approved human drug, verifiable via the FDA’s Orange Book. This is the path that makes semaglutide / tirzepatide / sermorelin acetate / oxytocin / PT-141 compoundable — those molecules are components of approved human drugs (Ozempic/Wegovy, Mounjaro/Zepbound, Geref/Sermorelin, Pitocin, Vyleesi respectively).

Where the major peptides currently sit (as of mid-2026, verified)

This is the practical answer to “what can my doctor prescribe through a compounding pharmacy right now?”

Compoundable in 503A right now

• Dutasteride — USP monograph, eligible. (5-alpha-reductase inhibitor for BPH + off-label hair loss.)
• Semaglutide, tirzepatide, liraglutide — components of approved human drugs. Compoundable but with significant FDA scrutiny since the GLP-1 class came off shortage. Requires physician justification of why the commercially available product isn’t suitable for the patient.
• Sermorelin acetate — component of approved human drug.
• Oxytocin — component of approved human drug.
• PT-141 / Bremelanotide — component of approved human drug.
• GHK (the copper peptide GHK-Cu) — on Category 1 BUT with an important asterisk: NOT for injectable use. Topical formulations only at this regulatory tier.
• Ganirelix acetate — component of approved human drug.
• VIP (vasoactive intestinal peptide) — Category 1.
• Tesamorelin — FDA-approved (Egrifta) for HIV-associated lipodystrophy; compoundable.

Category 2 — not compoundable as of mid-2026 (under PCAC review)

• TB-500 — Category 2.
• MOTS-c — Category 2.
• DSIP (Delta sleep-inducing peptide) — Category 2.

“Jury Still Out” — removed from Category 2 but not on Category 1 (regulatory limbo)

These have been REMOVED from the “do not compound” list but are NOT YET officially approved for compounding. Status as of mid-2026:

• BPC-157 — ✅ verified: REMOVED from Category 2 effective April 22, 2026. PCAC review scheduled July 23, 2026.
• Ipamorelin acetate — ✅ verified: removed from Category 2 effective September 27, 2024 (the nominator withdrew the substance nomination, triggering automatic removal).
• CJC-1295
• Thymosin Alpha-1
• Selank acetate
• AOD-9604
• KPV — pending PCAC review.
• Semax — pending PCAC review.
• Epithalon — pending PCAC review.
• Kisspeptin-10 — pending PCAC review.

The honest 2026 customer-facing read: when you ask your compounding pharmacy “can you make me BPC-157?” the current answer is essentially “we’re waiting on the July 2026 PCAC review to know whether we can legally make this.” Same answer applies to Ipamorelin, CJC-1295, TA1, Selank, AOD-9604, KPV, Semax, Epithalon. These compounds are available right now only through research-chemical vendors (Pathway 3).

The PCAC review — what's coming July 23, 2026

The Pharmacy Compounding Advisory Committee (PCAC) is the FDA advisory committee that reviews compounding-eligibility nominations and makes recommendations on which substances should appear on Category 1 of the bulks list. A PCAC review is scheduled for July 23, 2026 that will review multiple peptides currently in regulatory limbo, including BPC-157, TB-500, MOTS-c, DSIP, Semax, Epithalon, and KPV.

What PCAC recommendations actually mean:

• PCAC is advisory — the FDA can adopt their recommendation, modify it, or ignore it.
• If a compound is recommended for Category 1, the FDA still has to take formal regulatory action to move it there. That can take months after PCAC review.
• If a compound is recommended to stay on (or return to) Category 2, the FDA typically adopts that recommendation.

The realistic trajectory for BPC-157 (the example everyone’s watching):

• Currently in regulatory limbo (removed from Category 2 April 2026; not on Category 1).
• PCAC review July 23, 2026.
• IF PCAC recommends Category 1 and FDA adopts, compounding pharmacies could begin compounding BPC-157 — possibly months later.
• IF PCAC recommends Category 2 (back to “do not compound”), the limbo collapses to banned.
• Industry advocates (including the RFK Jr. / MAHA movement Matt and Nichollet reference) have been lobbying for Category 1 placement for over a year, with multiple rumored timelines that have come and gone.

Until PCAC results are published and FDA acts, compounding pharmacies legally cannot prepare these compounds for patients. Some smaller pharmacies and gym/med-spa operations do so anyway under various interpretations of “enforcement discretion”; the legal exposure for the pharmacy is real, and the FDA has shown willingness to act (the 2024 California facility shutdown is one documented example).

Pharma-grade COA standards vs research-chem COA standards

The COA discipline at the pharmacy-grade API wholesale level is substantially more rigorous than the research-chem COA standards covered in How to read a peptide Certificate of Analysis (and spot a fake). Both are real verification tools; they serve different supply chains.

A pharma-grade API COA must contain at minimum:

• Original manufacturer name + address (the actual chemistry-doing facility, not just the importer)
• Batch + lot numbers
• Expiration or retest dates
• Lab performing the test
• Quality review + release signature (if testing lab is not the original manufacturer)
• Acceptance criteria AND actual results (NOT just “pass/fail”)
• Identity testing (IDA, ID, IDB)
• Assay
• Water test
• Purity and related substances (including byproducts)
• Residual solvents per USP chapter 467
• Elemental impurities per USP chapters 232 and 233 (heavy metals: arsenic, cadmium, mercury, lead)
• Endotoxin and bioburden testing for sterile use products

This is governed by USP Chapter 1504 (✅ verified — “Quality Attributes of Starting Materials for the Chemical Synthesis of Therapeutic Peptides,” published December 1, 2023), 21 CFR 210 and 211 (the Code of Federal Regulations sections defining current Good Manufacturing Practice for pharmaceuticals), and ICH Q7 (the international harmonized standards for active pharmaceutical ingredient manufacturing).

Translation for the OHM customer: when you see a Janoshik COA from a research-chem vendor, that’s testing for purity + identity + quantity + endotoxin. When you see a pharma-grade COA from a 503A pharmacy’s API supplier (like Pharma Source Direct), that’s testing all of that PLUS heavy metals + residual solvents + elemental impurities + comprehensive impurity profile + quality-review signoffs. The pharma-grade COA is more comprehensive; that’s part of why pharma-grade peptides cost what they cost.

The pharma-grade API supply chain — who's actually making these

A small handful of B2B API wholesalers (Pharma Source Direct is one of several) source pharma-grade APIs from FDA-registered manufacturers and supply them to compounding pharmacies. To be a legitimate operator at this tier, a wholesaler must:

• Be FDA-registered as a drug facility
• Have NDC numbers registered with FDA (not just be registered as a manufacturer — the specific drug code matters)
• Have state board of pharmacy license where they exist AND where they sell
• Be DEA-registered as a drug establishment site
• Have a verifiable physical address (Matt’s note: multiple instances of “hotel room in middle of China” as registered address — verify physical presence)
• Have CGMP policies + procedures
• Use FDA-registered + inspected manufacturers as their actual source

Compounding pharmacies are required to vet their wholesalers to this standard. The pharmacies that don’t (or who source from cheaper unverified suppliers) face FDA warning letters, enforcement actions, and potential shutdown.

The reality this video reveals: during the GLP-1 shortage of 2022–2024, even some large compounding pharmacies were caught buying directly from China with Photoshopped COAs and hotel-room addresses. The “research-chem-quality supply chain failure” pattern that the JAMA SARMs study documented (43% of peptides failing Janoshik label purity claims) was happening at the regulated 503A/503B level too, not just the consumer gray market. This is part of why FDA enforcement scrutiny has tightened.

The "gym/med spa loophole" — why these operations sell peptides without consequence

You may have noticed: your local gym, med spa, “longevity clinic,” or wellness center may be openly selling injectable peptides — BPC-157, TB-500, semaglutide, etc. — that compounding pharmacies cannot legally prepare for patients. How does that work?

The honest answer: these operations don’t fall under FDA jurisdiction. FDA’s jurisdiction covers 503A pharmacies, 503B outsourcing facilities, wholesalers, and manufacturers. Gyms and med spas operating outside that framework — typically buying from offshore sources, repackaging, and selling cash — are operating in a regulatory gap. State boards of pharmacy and state medical boards have varying levels of activity addressing this.

The 2024 California enforcement case (a facility posing as a 503B but not actually registered as one — mass-producing compounds, shut down by FDA injunction) is the rare documented example of FDA acting against an operation outside its primary jurisdiction. Otherwise, enforcement at the gym/med spa tier is genuinely patchy.

For the OHM customer: this matters because if your local gym is selling you “compounded BPC-157,” it almost certainly is NOT compounded by a 503A or 503B pharmacy. It’s research-chem-supply-chain product, repackaged. The supply-chain reality is the same as if you bought it yourself from a research-chem vendor — except now you have an additional intermediary you can’t verify, paid markup to, and have less control over. Buying research-chem-supply product through a gym intermediary doesn’t change the supply chain; it just changes who profits from the markup. Independent verification (How to read a peptide Certificate of Analysis (and spot a fake)) is the right move regardless of where you bought it.

How OHM customers should think about choosing between the three pathways

The honest framework, no soft-pedaling:

Choose Pathway 1 (FDA-approved Rx) if:

• You want the highest regulatory grade and have insurance or budget that covers brand-name pricing.
• The peptide you want has an FDA-approved indication that matches your situation.
• Your doctor is willing to write the prescription.
• You’re OK with the narrower indication scope.

Choose Pathway 2 (compounded) if:

• The peptide you want is currently compoundable (see the status table above).
• You want pharmaceutical-grade quality control + medical oversight without brand-name pricing.
• You’re working with a clinician who’s familiar with the compounded peptide lane.
• You’re OK with substantially higher costs than research-chem (typically $200–1000+/month depending on compound + pharmacy).

Choose Pathway 3 (research chemical) if:

• The peptide you want is NOT currently compoundable (most of the popular ones: BPC-157, TB-500, MOTS-c, KPV, CJC-1295, Ipamorelin, etc.).
• OR you want compoundable peptides at substantially lower cost and you accept the supply-chain verification responsibility.
• You’re willing to do the COA verification work yourself (How to read a peptide Certificate of Analysis (and spot a fake)).
• You understand the regulatory positioning and accept it.

OHM’s recommended approach within Pathway 3: verified vendor + verified third-party COA + cap-and-seal color matching + the 8-step verification checklist from the COA literacy article. That’s the customer-protection framework that closes most of the actual supply-chain risk while giving you research-chem pricing.

A note on the “wait for July 2026 PCAC” question: if you’re specifically interested in BPC-157 or one of the other compounds currently in regulatory limbo, the PCAC review July 23, 2026 may move them into Category 1 (making them compoundable through pharmacies). It also may not. The honest answer: nobody knows what PCAC will recommend or how the FDA will act on the recommendation. Industry timelines have been wrong repeatedly. If you want access to these compounds now, Pathway 3 is the current option. If you want access through a compounding pharmacy specifically, you’re waiting on regulatory action with no committed timeline.

Cross-references in the wiki

• How to read a peptide Certificate of Analysis (and spot a fake) — the verification framework for research-chem peptides (Pathway 3). Pharma-grade COA standards covered above complement that.
• Where peptides are actually made — the global manufacturing reality — the manufacturing-geography deep-dive. Both compounded and research-chem peptides trace back to the same Chinese API supply chain; the difference is which intermediaries the molecule passes through before reaching you.
• The mainstream-medicine skeptical position — what the other side actually says — the mainstream-medicine “go legitimate” framing maps to Pathway 1 or Pathway 2 here.
• BPC-157 — current Category-2-removed-pending-PCAC-review status referenced.
• KPV — pending PCAC July 23-24 2026 review referenced.
• TB-500, MOTS-c — currently Category 2, under PCAC review.

---

Last updated: 2026-06-20. Created from the Atrium24 × Pharma Source Direct B2B webinar source video. All regulatory framework content independently verified against FDA, USP, Lexology, and pharmaceutical-industry sources. The bulks-list status table reflects mid-2026 state and will need refresh after the July 23, 2026 PCAC review. Monthly health-check should include re-checking the FDA bulks list for any status changes. All practitioner content paraphrased per Doctrine #3.